ArrowMark Colorado Holdings’s Neon Therapeutics, Inc. Common Stock NTGN Stock Holding History

ArrowMark Colorado Holdings’s Portfolio NTGN Stock Details NTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-703,375	Closed	-$3.33M	–	357
2019 Q2	$3.33M	Sell	703,375 -243,920	-26%	-$1.37M	0.03%	223
2019 Q1	$6.12M	Buy	947,295 +44,434	+5%	+$233K	0.06%	201
2018 Q4	$4.54M	Buy	902,861 +498,011	+123%	+$3.49M	0.05%	225
2018 Q3	$3.46M	Buy	404,850 +2,640	+0.7%	+$29.3K	0.03%	257
2018 Q2	$5.07M	Buy	+402,210	New	+$5.51M	0.05%	234

Other funds holding NTGN

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HMC

Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

ArrowMark Colorado Holdings's NTGN Position: Q3 2019 in Review

ArrowMark Colorado Holdings sold out of Neon Therapeutics, Inc. Common Stock (NTGN) in Q3 2019, closing a stake of 703,375 shares — an estimated $3.33M sold.

ArrowMark Colorado Holdings first reported a position in NTGN in Q2 2018 and held it in 5 quarters. The position peaked at $6.12M in Q1 2019. 58 funds tracked by Wall St. Rank hold NTGN as of Q3 2019.

ArrowMark Colorado Holdings reported no remaining Neon Therapeutics, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
ArrowMark Colorado Holdings sold 703,375 Neon Therapeutics, Inc. Common Stock shares in Q3 2019, an estimated $3.33M.
ArrowMark Colorado Holdings first reported a position in Neon Therapeutics, Inc. Common Stock in Q2 2018 and held it in 5 quarters.
ArrowMark Colorado Holdings's Neon Therapeutics, Inc. Common Stock position peaked at $6.12M in Q1 2019.
58 funds tracked by Wall St. Rank held Neon Therapeutics, Inc. Common Stock as of Q3 2019.

Based on ArrowMark Colorado Holdings's 13F filing for Q3 2019, filed 14 Nov 2019.